| Autor: |
Zulueta P; Albert Einstein College of Medicine, New York, NY 10461, USA., Minniti CP; Albert Einstein College of Medicine, New York, NY 10461, USA., Rai A; Albert Einstein College of Medicine, New York, NY 10461, USA., Toribio TJ; Department of Ophthalmology & Visual Sciences, Montefiore Medical Center, Albert Einstein College of Medicine, New York, NY 10461, USA.; Department of Pediatrics, Montefiore Medical Center, Albert Einstein College of Medicine, New York, NY 10461, USA., Moon JY; Department of Epidemiology & Population Health, Montefiore Medical Center, Albert Einstein College of Medicine, New York, NY 10461, USA., Mian UK; Department of Ophthalmology & Visual Sciences, Montefiore Medical Center, Albert Einstein College of Medicine, New York, NY 10461, USA.; Department of Pediatrics, Montefiore Medical Center, Albert Einstein College of Medicine, New York, NY 10461, USA. |
| Abstrakt: |
The American Academy of Ophthalmology and the National Heart, Lung and Blood Institute recommend patients with sickle cell disease (SCD) undergo dilated funduscopic exams (DFE) every 1-2 years to screen for sickle retinopathy. There is a paucity of data on the adherence rate to these guidelines; a retrospective study was performed to evaluate our institution's adherence. A chart review of 842 adults with SCD, seen 3/2017-3/2021 in the Montefiore healthcare system ( All Patients ), was done. Only about half of All Patients (n = 842) had >1 DFE during the study period ( Total Examined Patients , n = 415). The Total Examined Patients were categorized as screening, those without retinopathy ( Retinopathy- , n = 199), or follow-up, including individuals previously diagnosed with retinopathy ( Retinopathy+ , n = 216). Only 40.3% of screening patients (n = 87) had DFE at least biennially. As expected, there was a significant decrease in the average DFE rate of the Total Examined Patients after the COVID-19 pandemic started (13.6%) compared to pre-COVID (29.8%, p < 0.001). Similarly, there was a significant decrease in the screening rate of Retinopathy- patients from 18.6% on average pre-COVID to 6.7% during COVID ( p < 0.001). This data shows the sickle retinopathy screening rate is low and innovative approaches may need to be employed to remedy this issue. |
